a rate that is somewhat less than the 25% rate that was observed among women who received TDF for a mean duration of 8.6 weeks in an earlier study. The use of telbivudine for a median of 15.5 weeks resulted in no women with an HBV DNA level of more than 200,000 IU per milliliter at delivery. Nevertheless, no perinatal transmission was observed in these three studies.